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Guanylin is a peptide isolated from rat intestine that stimulates intestinal guanylate cyclase. We describe here the purification of circulating guanylin 
from human hemofiltrate. By N-terminal protein sequence analysis 47 amino acids were determined. This sequence corresponds to the positions 
22 to 68 of the prohormone deduced from the cDNA sequence of human proguanylin. Mass spectral analysis of the circulating peptide showed 
the molecular weight to be 10,336 Da, which corresponds to the mass calculated from position 22 to the C-terminus of the peptide predicted from 
the cDNA sequence. Circulating guanylin markedly increased the cyclic GMP content of T84 cells. Our data show that the hormonal form of 
guanylin is circulating as a 10.3-kDa peptide in human blood. 
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1. INTRODUCTION 
Guanylin is a 15-amino acid peptide isolated from rat 
intestine which stimulates intestinal guanylate cyclase 
(GC-C) [l]. Subsequent increases in epithelial cyclic 
GMP levels inhibit intestinal fluid absorption and in- 
crease chloride secretion [2]. 
Recently the human cDNA encoding this hormone 
was cloned [3,4]. The cDNA sequence revealed that the 
isolated peptide is the C-terminal end of a longer pro- 
guanylin molecule and possibly represents a truncated 
fragment of previous acetic acid extraction methods 
during the purification procedure. To our knowledge 
the correct processing site of proguanylin to the mature 
hormone has not been described. 
In-situ hybridization suggested that guanylin may be 
expressed in the Paneth cells of the small intestine and 
that the peptide acts as a local paracrine modulator of 
intestinal fluid transport [3]. However, at least in rat, 
guanylin-mRNA was also found in low amounts in 
other tissues, such as adrenal gland, kidney and uterus 
[5]. The same group reported for several species that the 
mRNA for GC-C, the apparent guanylin receptor, ex- 
ists not only in the epithelium of the gastrointestinal 
tract but also in other organs [5]. Thus, the actions of 
guanylin may ultimately extend to other tissues. The 
existence of guanylin in human blood plasma has not 
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been described yet. However, the possibility exists that 
guanylin is a circulating hormone modulating the func- 
tion of various organs by an endocrine mode. 
2. MATERIALS AND METHODS 
2.1. Bioassay for guanylin activity 
Guanylin-like bioactivity was assayed as described by Currie et al. 
[l]. In brief, T84 cells (human colon carcinoma cells; ATCC, Rock- 
ville. MD) were cultured in a 1 :l mixture of Ham’s F12 medium and 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 
10% heat-inactivated fetal calf serum, 50 U/ml of penicillin and 50 
@ml of streptomycin (Gibco). 
Experiments were performed with T84 cells at passages 59-68, 
grown to confluence in 24-well plates. Before starting the experiments 
the cells were washed three times with 0.5 ml DMEM and then incu- 
bated at 37°C for 10 min with 0.25 ml DMEM containing 1 mM 
isobutylmethylxanthine (IBMX, Sigma), a cyclic nucleotide 
phosphodiesterase inhibitor. Agents and fractions derived from the 
chromatographic steps were lyophilized, dissolved in 0.1 ml DMEM, 
and added to the wells for 60 min. Then the incubation medium was 
aspirated and the reaction was terminated by addition of 0.1 ml ice- 
cold 70% ethanol. After freeze-thawing, the wells were dried by evap- 
oration and 1 ml of 50 mM sodium acetate buffer (pH 6.0) was added 
to each well. Supematant fractions were acetylated and cyclic GMP 
was measured by radioimmunoassay [6]. 
2.2. PuriJcation of guanylin 
As a source for human plasma peptides we used hemofiltrate, col- 
lected from patients with chronic renal failure. This material offers 
several advantages: (1) it is available in large quantities; and (2) he- 
mofiltration constitutes a first purification step of plasma peptides, 
since the cutoff of the hemofilter, 20,000 Da, reduces the amount of 
filtered proteins to a minimum. Hemofiltrate was obtained from renal 
insufficient patients at a local hospital (Niedersiichsisches Zentrum fur 
Nephrologie, Hannoversch-Miinchen, Germany). The first step of 
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isolation was carried out according to a modification [7] of the pol- 
ypeptide isolation by Mutt [8]. After its collection hemofiltrate was 
immediately acidified with pure hydrochloric acid (HCl) by pH 3.5. 
A batch of 720 liters was diluted 1: 1 (v/v) with water, adjusted to pH 
2.7 by concentrated HCI, and stirred for 18 h after adding 2.5 kg of 
alginic acid. The batch was then filtered on a Biichner funnel to obtain 
the dry alginic acid with absorbed peptides. Subsequently the alginic 
acid was washed with 98% ethanol (v/v) and 0.005 N HCl. The pol- 
ypeptides were then eluted with ice cold 0.2 N HCl. After lyophiliza- 
tion, 6.5 g of the extract (to!al weight: 46.5 g) which corresponds to 
100 liters of hemofiltrate were resuspended in 100 ml of 0.01 N HCI 
and centrifuged at 2,500 x g for 20 min at 4°C. The supematant was 
filtered and applied in 4 ml fractions to a preparative reversed-phase 
(RP) C4 column (300 A, 20-45 pm, 30 x 125 mm) (Parcosil, Biotek, 
Heidelberg, Germany). The samples were eluted with a flow rate of 
5 ml/min and fractionated with the following gradient: 0.01 N HCl 
(buffer A) to 80% acetonitrile (v/v), 0.01 N HCl (buffer B) in 120 min 
(Step. An aliquot of each fraction was tested in the bioassay with 
T84 cells. The bioactive fractions were pooled and submitted to six 
RP-HPLC steps. After each step aliquots of all fractions were tested 
in the bioassay, and the active fractions were processed for further 
purification. The following HPLC conditions were used for the purifi- 
cation of guanylin bioactivity: S&&column RP C4, Parcosil, 250 A, 
2&45 pm, 20 x 125 mm: gradient from 0.1% trifluoroacetic acid 
(TFA) to 80% 2-propanol, 0.1% TFA in 120 min; flow rate, 3 ml/min; 
m, column RP C4, Parcosil, 300 A, 5 pm, 10 x 125 mm; gradient 
from 30% acetonitrile, 0.1% TFA to 80% acetonitrile, 0.1% TFA in 
150 min; flow rate, 2 ml/min; Step, column RP C18, Parcosil, 100 
A, 5 pm, 4 x 250 mm; gradient from 20% acetonitrile, 0.1% TFA to 
60% acetonitrile, 0.1% TFA in 80 min; flow rate, 0.7 ml/mm. The last 
three steps of purification were carried out on a microbore RP Cl8 
column (300 A, 5 pm, 2.1 x 100 mm) (Vydac, Hesperia, CA, USA) 
with a flow rate of 0.2 mllmin. The following gradients were used: 
step, 30% acetonitrile. 0.01 N HCl to 60% acetonitrile, 0.01 
N HCl in 60 min; Ste~&O.08% heptafluorobutyric acid to 30% meth- 
anol, 50% 2-propanol. 0.08% heptafluorobutyric acid in 80 min; 
Step, 20% methanol, 0.1% TFA to 100% methanol, 0.08% TFA in 
100 min. In the last purification step a single bioactive fraction was 
obtained. Capillary zone electrophoresis of an aliquot of this fractron 
showed a single peak. This highly purified material was submitted to 
amino acid sequence analysis and mass spectrometry. 
2.3. Sequence analym 
Amino acid sequencing was carried out on an ABI 470A gas-phase 
sequencer equipped with an ABI 120A PTH-ammo acid analyser 
(Applied Biosystems, Weiterstadt, Germany) using the 03CPTH pro- 
gram, the standard gradient and a Kontron data system. 20 to 500 pM 
of the peptide or the fragments were apphed onto the BIOPRENE- 
coated glass fibre discs. 
2.4. Mass spectrometry 
Mass determination of the purified peptide was carried out on a 
Finnigan TSQ700 triple stage quadrupol mass spectrometer in single 
MS mode with ES1 interface. Sample introduction of the peptide was 
performed via a Harvard syringe pump with a flow rate of 2 pl/min. 
2.5. Peptide synthesis 
Synthesis of rat guanylin [I] was performed on a continuous-flow 
synthesis using standard Fmoc-protocols for activation and cleavage 
reactions [9]. The disulphide bridges were introduced selectively by 
using Fmoc-Cys (Trt) and Fmoc-Cys (Acm) with subsequent au and 
iodine oxidatton procedures. After purification (Cl8-RP chromatog- 
raphy) purity and identity were checked by HPLC. CZE and mass 
analysis. 
2.6. Capillary _-one elecrrophoresis 
CZE was carried out with a P/ACE 2000 (Beckman, Miinchen, 
Germany). Condttions were: buffer, 0.1 M phosphate, pH 2.5; con- 
stant current 80 mA, detection 200 nm, fused silica capillary 50 
cm x 75 pm [lo]. 
3. RESULTS 
Initial characterization of the T84 cells revealed that 
nitric oxide donors like SIN-l (Cassella Riedel, Ger- 
many) and sodium nitroprusside (Sigma) have no effect 
on their cyclic GMP content. Incubation of T84 cells 
with natriuretic peptides like CDD/ANP-99-126 
(olhANP) and CDD/ANP-95-126 (urodilatin) (both 
Saxon Biochemicals, Germany), induced a small in- 
crease in cyclic GMP to maximally 4-fold at 0.1 PM of 
100000 : 
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Fig. 1. Effect of stimulators of particulate guanylate cyclase GC-C (guanylin and STa) and GC-A (CDD/ANP-99-126 and CDD/ANP-955126) 
on cyclic GMP content in T84 cells. Cells were incubated with the indicated concentrations during 60 min m the presence of 1 mM IBMX. Values 
represent means f S.E. (n = 4). 
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Fig. 2. Representative chromatograms obtained during purification of 
human guanylin from hemofiltrate. HPLC conditions are given in 
section 2. B: eluent B (%, v/v). Hatched columns indicate the bioactive 
fractions (means of two determinations). irANP: immunoreactive 
CDD/ANP-99-126. Steps 4 and 7: asterisks indicate the fractions 
submitted to amino acid analysis and mass spectrometry; resting cyclic 
GMP content of T84 cells in the corresponding bioassays was 178 ? 22 
fmol/well (mean + S.E., n = 4); T84 cyclic GMP content was increased 
by four successive fractions at Step 4 and a single fraction at Step 7; 
at the right of both graphs, concentration-dependent stimulation of 
T84 cyclic GMP by enterotoxin (STa: 10 pM to 10 nM) (means f SE., 
n = 2). 
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21 22 
MetAsnAlaPheLeuLeuPheAlaLeuCysLeuLeuGlyAlaTrpAlaAlaLeuAlaGlyGlyValThrValGln 
ValThrValGln 
AspGlyAsnPheSerPheSerLeuGluSe~-ValLysLysLeuLysAspLeuGlnGluProGlnGluProArgVal 
AspGlyAsnPheSerPheSerLeuGiuSerVcllLysLysLeuLysAspLeuGlnGluProGlnGluProArgVal 
68 
GlyLysLeuArgAsnPheAlaProIleProGlyGluProValValProIleLeuCysSerAsnProAsnPhePro 
GlyLysLeuArgAsnPheAlaP2-olleProGlyGluProVa1Va1Pr-oIleLeu.................... 
GluGluLeuLysProLeuCysLysGluProAsnAlaGlnGluIleLeuGlnArgLeuGluGluIleAlaGluAsp 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
115 
ProGlyThrCysGluIleCysAlaTyrAlaAlaCysThrGlyCys Calculated mass:10,337(pos.22-115) 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Determined mass:10,336 
Fig. 3. Comparison between the amino acid sequence determined for the peptlde purified from hemofiltrate (it&) and the sequence of human 
proguanylin deduced from the cDNA sequence [3,4]. Numbers above the sequence refer to the amino acid posltlon. 
both peptides (Fig. 1). In contrast, heat-stable entero- 
toxin (STa, Sigma) and synthetic guanylin induced large 
increases in cyclic GMP level, up to 555fold at 0.1 PM 
STa and 202-fold increase from basal levels at 0.1 ,uM 
synthetic rat guanylin (Fig. 1). Thus, T84 cells are sensi- 
tive and rather specific detector cells for guanylin activ- 
ity in human plasma. 
Purification of bioactive material was accomplished 
as described in section 2. After polypeptide extraction 
with the alginic acid method, the material was chroma- 
tographed on a preparative C4-RP column (Step 1). The 
fractions with maximal bioactivity eluted between 69 
and 70% buffer B (Fig. 2). As a control, an aliquot of 
each fraction was also tested for circulating CDD/ANP- 
999126 by radioimmunoassay. Fractions containing im- 
munoreactivity eluted at 46% buffer B. The bioactive 
fractions were then purified to homogeneity by a series 
of subsequent RP-HPLC steps (see section 2 and Fig. 
2). During chromatographic Step 4, four successive 
fractions contained bioactivity. CZE of an aliquot of 
each fraction revealed that one of them consisted of 
almost pure material. This fraction was subjected to 
N-terminal protein sequence analysis and to electros- 
pray mass spectrometric analysis. The amino acid se- 
quence as indicated in Fig. 3, is homologous with posi- 
tions 22 to 68 of the guanylin precursor deduced from 
the human cDNA sequence [3,4]. The further amino 
acid sequence is suggested from mass spectrometry of 
the extracted peptide revealing a molecular weight 
(MW) of 10,336 Da. This MW corresponds exactly to 
the calculated mass for the positions 22 up to the C- 
terminus (position 115) of proguanylin deduced from 
human cDNA. This active fraction contained approxi- 
mately 500 pmol of the peptide, in a total fraction- 
volume of 700 ,ul (concentration: 0.7 PM). An aliquot 
of 25 ~1 of this sample (approximately 18 pmol of the 
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bioactive material: 9 pmol/well, corresponding to a con- 
centration of 26 nM) stimulated the cyclic GMP content 
of T84 cells by 9-fold. For comparison, in the same 
experiment, 10 nM STa (5 pmol/well) induced a 14-fold 
increase in cyclic GMP content of T84 cells (Fig. 2, Step 
4). 
The other three bioactive fractions of this chromato- 
graphic step were refractionated on a microbore C18- 
HPLC column (purification Steps 5-7, section 2). Fi- 
nally, a single bioactive fraction was obtained. CZE of 
an aliquot of this fraction resulted in a single peak. 
N-terminal protein sequence analysis resulted again in 
the sequence starting with: Val-Thr-Val-Gln-Asp-Gly- 
Asn-. . These N-terminal amino acids indicated that 
this material was identical to the material sequenced in 
the chromatographic Step 4. In the bioassay, a 5-~1 
aliquot of this sample (this is, 5% volume of the whole 
sample volume) led to a lo-fold stimulation of cyclic 
GMP content in T84 detector cells. For comparison the 
same activity was yielded by 1 nM STa (0.5 pmol/well) 
(Fig. 2, Step 7). As illustrated in Fig. 2, the responsive- 
ness of T84 cells to STa was markedly greater in the 
bioassay performed at Step 7 as compared to Step 4. 
The difference is probably attributable to the fact that 
the cells were used at different passages (Step 4, passage 
64; Step 7, passage 61). 
4. DISCUSSION 
In the present study we describe the purification and 
sequence of the circulating form of human guanylin. 
This is for the first time that the existence of guanylin 
in human blood has been proven including its exact 
molecular form. 
Hemofiltrate was purified by a series of reverse-phase 
HPLC fractionation steps using T84 cells as sensitive 
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detector cells of guanylin activity. This procedure led to 
the final isolation of a 10,336-Da peptide. By N-termi- 
nal protein sequence analysis 47 amino acids of the 
circulating peptide could be determined. This sequence 
is in accordance with the amino acids in positions 22 to 
68 deduced recently for human intestinal proguanylin 
from the cDNA sequence [3,4]. The mass determined 
for the circulating peptide corresponds exactly to that 
calculated for the positions 22 up to the C-terminus of 
proguanylin deduced from the cDNA. Our data 
strongly suggest hat a high molecular form of guanylin 
is circulating in human blood. However, since the com- 
plete sequence of the circulating peptide was not ob- 
tained, the possibility exists that its C-terminus is differ- 
ent to that deduced from human guanylin cDNA [3,4]. 
From the cDNA the sequence of a 115 amino acid 
prohormone was predicted (see Fig. 3). The C-terminus 
contains the 15 amino acid sequence published for rat 
intestinal guanylin [ 11. The correct processing site of the 
mature peptide has not been described until now. Our 
data suggest hat the physiological cleavage site of the 
prohormone to a circulating peptide is between posi- 
tions 21 and 22. However, other naturally occurring 
processing forms cannot be excluded. Transfection of a 
human embryonic kidney cell line with the full-length 
human cDNA led to the secretion of a 94 amino acid, 
10,337 Da protein [3]. Obviously, this MW corresponds 
to that we have found for the circulating plasma pep- 
tide. In our hands ‘high molecular weight’ guanylin is 
very bioactive (as related to cyclic GMP formation in 
T84 cells). In contrast, the conditioned media of pro- 
guanylin-transfected cells apparently were not bioactive 
(no displacement of [“‘I]STa binding) [3]. Possible ex- 
planations are that our assay is more sensitive than the 
one used by these authors or that the concentrations of 
guanylin in the supernatants of the transfected cells 
were too low to be effective. Also it cannot be excluded 
that interaction with T84 cells led to the proteolytic 
cleavage of the circulation peptide into an active gua- 
nylin. 
The purified hemofiltrate fraction contained approxi- 
mately 500 pmol of the bioactive peptide. At this stage 
of purification (Step 4) the sequenced fraction was one 
of four fractions with similar amount of bioactive mate- 
rial. Thus, a calculated amount of approximately 2 
nmol guanylin was purified from 100 liters of hemofil- 
trate. Disregard to the inevitable loss of material during 
the purification, this concentration is rather high. Since 
hemofiltrate was obtained from renal insufficient pa- 
tients we cannot exclude that the high circulating levels 
are due to impaired renal metabolism or decreased renal 
elimination of the peptide. 
At the moment only speculations are possible about 
the cellular source of circulating bioactive guanylin. 
Northern analysis showed that guanylin-mRNA is 
prevalent in intestine and it was suggested that the pep- 
tide is a local regulator of intestinal fluid transport [3,4]. 
If this is true, plasma guanylin may just be a kind of 
‘overflow’ of a local hormone. However at least in rat, 
low mRNA levels were found outside the intestine: in 
adrenal gland, kidney and uterus [5]. Moreover, North- 
ern analysis of GC-C and binding studies with [‘251]STa 
suggest hat the guanylin receptor is present in other 
epithelial cells [5,1 I]. Thus the actions of guanylin may 
ultimately extend to other tissues beside the intestine. 
From the fact that high molecular weight guanylin 
circulates in human plasma in a biologically active 
form, a lot of questions arise. Future studies will clarify 
whether this is just an ‘overflow’ phenomenon of a local 
hormone system or whether guanylin forms part of an 
endocrine pathway that modulates fluid secretion of 
various organs. 
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